+
Site Tour

Search

Showing 111 - 120 of 534 results.

  • Patients who benefit

    SWITCH TO THE REFERRAL VIEW    For more information specific to neurology regarding PFO closure  BACK TO WALKING 12 MILES PER DAY
  • Guidelines & Recommendations

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding LAA Occlusion 2024 EUROPEAN SOCIETY OF CARDIOLOGY (ESC) GUIDELINES FOR THE…
  • Patients who benefit

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding LAA Occlusion …
  • Overview

    SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding LAA Occlusion AF AND THE CHALLENGES OF MEDICATION Many patients at risk of…
  • EPIC™ Max Clinical Data

    AT 10 YEARS LEARN MORE: EPIC MAX BROCHURE COMMITED TO VALVE-IN-VALVE* FOLLOW-UP DATA 3-YEAR OUTCOMES OF VALVE-IN-VALVE INTERVENTION IN A U.S. POPULATION Maximizing the internal orifice…
  • Clinical Data

    SVD: structural valve deterioration. *From stand-alone aortic or mitral valve replacements.   THE EPIC PLATFORM HAS DEMONSTRATED EXCELLENT DURABILITY IN YOUNGER PATIENTS The Epic Mitral…
  • Classification

    aThis algorithm can be applied to all patients with advanced HF defined according to the HFA-ESC criteria,5 with exception of hypertrophic cardiomyopathy (HCM), cardiac arrest (CA), arrhythmic…
  • Guidelines & Recommendations

    2024 EUROPEAN SOCIETY OF CARDIOLOGY (ESC) GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPED IN COLLABORATION WITH THE EUROPEAN ASSOCIATION OF CARDIOTHORACIC SURGERY (EACTS)4-7 ACCESS…
  • Prevention

    AF AND THE CHALLENGES OF MEDICATION Many patients at risk of stroke want an alternative to oral anticoagulants (OACs), for example, warfarin and non-vitamin K oral anticoagulants (NOACs).7 40% Do…
  • Guidelines & Recommendations

    Compelling data resulted in positive guidelines recommending PFO closure Long-term data from the both the RESPECT trial12 and REDUCE trial,13 as well as data from the CLOSE trial,14 have revealed…

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline